U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs
Go back to U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 66.81 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.81 | 52 Week High | $77.12 | |||
| Open | $66.81 | 52 Week Low | $49.03 | |||
| Day High | $66.81 | P/E | 43.38 | |||
| Day Low | $66.81 | EPS | $1.54 | |||
| Volume | 6,715 | |||||
